Clinical trial
A PHASE 3, MULTICENTER, RANDOMIZED, LONG TERM STUDY OF THE SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
NCT00809783 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A PHASE 3, MULTICENTER, RANDOMIZED, LONG TERM STUDY OF THE SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
- Lead sponsor
- Pfizer
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- February 6, 2009
- Completion date
- June 23, 2011
- Enrollment
- 2,147 (actual)
- Sites
- 226
Conditions
As the registry lists them; a condition with its own page is linked.